Information:
Fel:
ID
13808
Beskrivning
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT01352650
Länk
https://clinicaltrials.gov/show/NCT01352650
Nyckelord
Versioner (1)
- 2016-03-07 2016-03-07 -
Rättsinnehavare
CC BY-NC 3.0
Uppladdad den
7 mars 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Acute Myeloid Leukemia NCT01352650
Eligibility Acute Myeloid Leukemia NCT01352650
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myeloid Leukemia NCT01352650
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
AML
Item
unequivocal pathologic diagnosis of aml (≥ 20% blasts in the bone marrow based on who criteria) excluding: i) acute promyelocytic leukemia t(15;17)(q22;q12); pml-rara; ii)acute myeloid leukemia with t(8;21)(q22;q22); runx1-runxt1; iii) acute myeloid leukemia with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); cbfb-myh11.
boolean
C0023467 (UMLS CUI [1])
C0023487 (UMLS CUI [2])
C0023487 (UMLS CUI [2])
AML
Item
aml patients with an antecedent hematologic disorder or myelodysplastic syndrome (mds)are eligible for treatment on this trial provided that they have not received prior treatment with decitabine or prior cytotoxic treatment for aml.
boolean
C0023467 (UMLS CUI [1])
C3463824 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0049065 (UMLS CUI [3])
C3463824 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0049065 (UMLS CUI [3])
therapy-related myeloid neoplasms
Item
aml patients with therapy-related myeloid neoplasms (t-mn) are eligible if they have not received chemotherapy (not including hormonal therapy) for their primary malignancy or disorder for >6 months.
boolean
C2939461 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C2924519 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2])
C0087111 (UMLS CUI [1,2])
C2924519 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2])
age
Item
age ≥ 60 years.
boolean
C0001779 (UMLS CUI [1])
informed consent
Item
ability to understand and willingness to sign a written informed consent document.
boolean
C0021430 (UMLS CUI [1])
prior treatment with decitabine
Item
prior treatment with decitabine
boolean
C0049065 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,2])
prior treatment with plerixafor
Item
prior treatment with plerixafor
boolean
C1955474 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,2])
concurrent therapy for another malignancy
Item
ongoing treatment for another malignancy.
boolean
C0006826 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0205420 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,2])
C0205420 (UMLS CUI [1,3])
molecular or cytogenetics features
Item
patients with good-risk molecular or cytogenetics features
boolean
C0010802 (UMLS CUI [1])
C1521991 (UMLS CUI [2])
C1521991 (UMLS CUI [2])
comorbidity limiting study protocol
Item
patient has a medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational drug treatment.
boolean
C2348563 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
comorbidity limiting consent and completion
Item
patient has a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies.
boolean
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
compliance behaviour
Item
patient has an inability or unwillingness, in the opinion of the investigator, to comply with the protocol requirements.
boolean
C1321605 (UMLS CUI [1])